Help Save People s World
The economic crisis has hit People s World hard. We need the support of all our friends and readers to continue publishing.
Toxic legacy, part 2: Fighting for justice after chemical warfare in Vietnam June 3, 2021 11:24 AM CDT By Amiad Horowitz
Two patients suffering with injuries caused by Agent Orange who are cared for at the Center for Nurturing and Treatment of Agent Orange/Dioxin Victims near Hanoi. | Photo courtesy of Bùi Vũ
The following article is the second in a two-part series on U.S. chemical warfare in Vietnam. The first part, which can be read here, dealt with the history of Agent Orange and its use by the U.S. military in Southeast Asia. This installment covers the stories of the victims and their battle for justice.
GENEVA, SWITZERLAND / ACCESSWIRE / June 2, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company with its lead compound RLF-100 (aviptadil) in advanced clinical
EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Miscellaneous02.06.2021 / 07:00 Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug Administration Geneva, Switzerland, Ju.
Search jobs 25-May-2021 Relief s Partner Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021 Following Pre-NDA Meeting with FDA
EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Miscellaneous
25.05.2021 / 07:00
Relief s Partner Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021 Following Pre-NDA Meeting with FDA
Newton, MA, USA and Geneva, Switzerland, May 25, 2021 - Acer Therapeutics Inc. (Nasdaq: ACER)( Acer ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, and RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF)( Relief ), a biopharmaceutical company with its lead compound RLF-100
Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021 Following Pre-NDA Meeting with FDA streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.